Aegerion To Plead Guilty, Pay $40M To Settle Justice, SEC Investigations

Mealey's (May 13, 2016, 10:07 AM EDT) -- CAMBRIDGE, Mass. — Aegerion Pharmaceuticals Inc. on May 12 said in a press release that it will plead guilty to federal misdemeanor violations and pay about $40 million to settle investigations by the U.S. Department of Justice and the Securities and Exchange Commission into its sales activities related to the marketing of its cholesterol drug Juxtapid.

Aegerion says the $40 million will be paid to the Justice Department and the SEC in quarterly installments over five years, plus 1.75 percent interest per year. The company says...
To view the full article, register now.